The global hepatitis diagnostic test market size was valued at USD 5.41 Billion in 2022 and is anticipated to reach USD 8.04 Billion by 2031 expanding at a substantial CAGR of 4.5% during the forecast period, 2023–2031. The growth of the market is attributed to the rising cases of hepatitis along with increase in awareness of the disease and rising need to identify the type of virus.
Hepatitis is characterized as inflammation of the liver. It is categorized on the basis of different type of viruses as Hepatitis A, B, and C. The disease is diagnosed by the type of virus present in the blood of the patient or the other method is by identifying the antibodies developed in the body against the virus.
The genetic testing of hepatitis includes molecular diagnostics to confirm the exact strain of the virus. One key aspect of the market expansion is due to the rapid development of modern diagnostic technologies such as nucleic acid assays, which include HBV DNA and HCV RNA analysis tests. The development leads to provide effective and accurate diagnostic results with shorter duration.
This disorder, without having access to early detection and a proper treatment, is likely to lead various severe health conditions including liver cirrhosis, liver cancer, and fibrosis or scarring in liver. The infection of hepatitis can occur due to factors such as viral infection, toxins, alcohol, side effects of medications or drugs, and autoimmune hepatitis.
According to World Health Organization (WHO), liver cancer is caused mainly due to hepatitis and the disorder is responsible for nearly 80% of all cases related to liver cancer reported globally with nearly 1.5 million deaths annually. The report also states that about 310 chronic cases are recorded worldwide.
As per the U.S. Department of Health & Human Services, around 37% of newly recorded chronic hepatitis C cases are occurred to the people between the age of 20 to 30 years in 2018 and this is anticipated to surge during the forecast period.
Hepatitis Diagnostic Test Market Trends, Drivers, Restraints, and Opportunities
- High prevalence of hepatitis globally, rising number of blood transfusions and donations, and awareness initiatives about the disease are expected to boost the market expansion during the forecast period.
- Rising growth of medical tourism, growing disposable income of consumers, and the rising great demography of undiagnosed people are the key factors driving the market.
- Increasing research and development activities, technological developments in the healthcare sector, and emerging markets are creating new opportunities for the market development.
- Deficiency of any compulsory directive issued by the authorities in developing countries as well as high cost of Nucleic Acid Amplification Testing (NAT) for the testing of hepatitis virus are proving to be major restraints to the market growth.
Scope of Hepatitis Diagnostic Test Market Report
The report on the global hepatitis diagnostic test market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Hepatitis Diagnostic Test Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Tests (Blood Tests [Immunoassays, Nucleic Acid Tests, and Liver Function Tests], Imaging Tests, and Liver Biopsy)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Abbott Laboratories; F. Hoffmann La-Roche; bioMeriuex; MedMira; Inc.; DiaSorin S.p.A; Hologic; Inc.; Siemens Healthineers; Danaher Corporation; and Bio-Rad Laboratories.
|
Hepatitis Diagnostic Test Market Segment Insights
Tests Segment Analysis
Based on tests, the global hepatitis diagnostic test market is segregated into blood tests, imaging tests, and liver biopsy. The blood test segment is further classified into immunoassays, nucleic acid tests, and liver function tests.
The blood test segment is anticipated to expand at a robust pace in the coming years as it is considered to the wide available and most adopted diagnosis test for detecting hepatitis and its treatment. In the blood test, the liver function test is most widely used for liver diseases, which is why the segment has showed promising results to flourish during the projected period.
To detect the presence of a specific virus in the sample, immunoassays test are primarily adopted as the test utilizes antibodies and antigens to perform the detection. Techniques such as PCR system, ELISA, RIBA, and CLIA are used to perform immunoassays that are expensive for most of the patients around the world.
Meanwhile, the imaging test is projected to exhibit a high CAGR during the forecast period owing to its wide adoption for the screening process. The test is basically performed to confirm the results of blood test; thereby, showing lucrative potentials for the segment growth.
On the other hand, the liver biopsies segment is expected to hold a considerable market share as it is performed to detect the viral strain in case of chronic conditions. Biopsies are used to identify cancer cells in liver after hepatitis infection.
Regional Analysis
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a major share of the market in the coming years owing to the availability of advanced diagnostic tools and high awareness regarding the healthcare products.
Moreover, wide establishment of proper infrastructure for healthcare services and the availability of skilled professional in the region present key factors driving the regional market growth. The growth of the market in the region is further attributed by the development of several government and non-government organizations’ awareness initiative.
For example, The Public Health Agency of Canada arranged the World Hepatitis Day to increase awareness concerning hepatitis diagnostics. Meanwhile, the market of Asia Pacific is anticipated to expand at a significant CAGR during the forecast period owing to wide incidence of hepatitis cases and growing per capita income of a large number of consumers in the region.
Increasing concerns from government agencies to develop advanced healthcare facilities and equipment has created a huge opportunity to proliferate the market growth in the region. According to the WHO reports, the prevalence of hepatitis Type B in South East Asia is approximately 0.7% as well as the incidence rate of HCV infection is 1.48 in 1,000,000 people.
Segments
The global hepatitis diagnostic test market has been segmented on the basis of
Tests
- Blood Tests
- Immunoassays
- Nucleic Acid Test
- Liver Function Test
- Imaging Tests
- Liver Biopsy
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the global hepatitis diagnostic test market include Abbott Laboratories; F. Hoffmann La-Roche; bioMeriuex; MedMira; Inc.; DiaSorin S.p.A; Hologic; Inc.; Siemens Healthineers; Danaher Corporation; and Bio-Rad Laboratories.
Some of these key players are consistently engaged in to adopt several market strategies including product launches, acquisitions, collaborations, and capacity expansion to enhance their market position.
Request For Customization
Enquiry Before Buying
Speak With Analyst
